Surrey researchers Sign in
Back
Real world evidence on the prescribing trends of glucagon-like peptide-1 agonists in UK primary care
Conference presentation   Peer reviewed

Real world evidence on the prescribing trends of glucagon-like peptide-1 agonists in UK primary care

W Hinton, A McGovern, J van Vlymen, N Munro, MB Whyte and S de Lusignan
Diabetic Medicine, Volume 33, Issue Supplement S1, March 2016 Special Issue: Abstracts of the Diabetes UK Professional Conference 2016, Vol.33(Supple), pp.165-165
Diabetes UK Professional Conference 2016 (Scottish Exhibition and Conference Centre, Glasgow, 2-4 March 2016, 02/03/2016 - 04/03/2016)
03/2016
DOI: https://doi.org/10.1111/dme.45_13048

Abstract

Nutrition
Aim The use of glucagon-like peptide-1 (GLP-1) agonists in type 2 diabetes is increasing. We present a description of their current use and prescribing trends in UK primary care and compare the characteristics of people prescribed GLP-1 agonists with phase 3 trial populations.
url
http://www.mcgov.co.uk/publicwork/View
Author

Metrics

34 Record Views

Details

Usage Policy

Usage details for all content viewed and downloaded in this site are shared with IRUS-UK (Institutional Repository Usage Statistics UK). Cookies are used to remember your decision. Click Accept to accept usage details sharing and the cookies.

Learn more